Tags

Type your tag names separated by a space and hit enter

Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy.
Am J Hypertens. 2005 Jul; 18(7):922-9.AJ

Abstract

We investigated whether prevention of cardiac and vascular remodeling associated with inhibition of angiotensin II is independent of the blood pressure (BP)-lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a videographic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11.5+/-0.4%; atenolol: 13.3+/-0.6%; vehicle: 18.4%+/-1.1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP.

Authors+Show Affiliations

Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

16053988

Citation

Yokoyama, Hiroshi, et al. "Role of Blood Pressure Reduction in Prevention of Cardiac and Vascular Hypertrophy." American Journal of Hypertension, vol. 18, no. 7, 2005, pp. 922-9.
Yokoyama H, Averill DB, Brosnihan KB, et al. Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens. 2005;18(7):922-9.
Yokoyama, H., Averill, D. B., Brosnihan, K. B., Smith, R. D., Schiffrin, E. L., & Ferrario, C. M. (2005). Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. American Journal of Hypertension, 18(7), 922-9.
Yokoyama H, et al. Role of Blood Pressure Reduction in Prevention of Cardiac and Vascular Hypertrophy. Am J Hypertens. 2005;18(7):922-9. PubMed PMID: 16053988.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. AU - Yokoyama,Hiroshi, AU - Averill,David B, AU - Brosnihan,K Bridget, AU - Smith,Ronald D, AU - Schiffrin,Ernesto L, AU - Ferrario,Carlos M, PY - 2004/08/03/received PY - 2004/12/29/revised PY - 2005/01/16/accepted PY - 2005/8/2/pubmed PY - 2005/11/10/medline PY - 2005/8/2/entrez SP - 922 EP - 9 JF - American journal of hypertension JO - Am J Hypertens VL - 18 IS - 7 N2 - We investigated whether prevention of cardiac and vascular remodeling associated with inhibition of angiotensin II is independent of the blood pressure (BP)-lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a videographic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11.5+/-0.4%; atenolol: 13.3+/-0.6%; vehicle: 18.4%+/-1.1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP. SN - 0895-7061 UR - https://www.unboundmedicine.com/medline/citation/16053988/Role_of_blood_pressure_reduction_in_prevention_of_cardiac_and_vascular_hypertrophy_ L2 - https://academic.oup.com/ajh/article-lookup/doi/10.1016/j.amjhyper.2005.01.009 DB - PRIME DP - Unbound Medicine ER -